The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes.
We examined the prevalence of hepatitis C virus (HCV) infection among HIV-positive individuals in the UK, trends in HCV testing and the impact of HCV on HIV treatment outcomes. Trends over time in HCV prevalence were calculated using each patient's most recent HCV status at the end of each calendar year. Logistic regression was used to identify factors associated with having a HCV antibody test, and Cox regression was used to determine whether HCV status was associated with the time to experiencing an immunological response to highly active antiretroviral treatment (HAART), time to virological response and viral rebound. Of the 31,765 HIV-positive individuals seen for care between January 1996 and September 2007, 20,365 (64.1%) individuals were tested for HCV, and 1807 (8.9%) had detectable HCV antibody. The proportion of patients in follow-up ever tested for HCV increased over time, from 782/8505 (9.2%) in 1996 to 14,280/17,872 (79.9%) in 2007. Nine thousand six hundred and sixty-nine individuals started HAART for the first time in or after January 2000, of whom, 396 (4.1%) were HCV positive. Presence of HCV infection did not affect initial virological response, virological rebound or immunological response. The cumulative prevalence of HCV in the UK CHIC Study is 8.9%. Despite UK guidelines, over 20% of HIV-positive individuals have not had their HCV status determined by 2007. HCV infection had no impact on HIV virological outcomes or immunological response to HIV treatment. The long-term impact on morbidity and mortality remain to be determined.
Turner
J
J
Centre for Sexual Health and HIV Research, UCL Medical School and The Mortimer Market Centre, Camden Primary Care Trust, London, UK.
Bansi
L
L
Gilson
R
R
Gazzard
B
B
Walsh
J
J
Pillay
D
D
Orkin
C
C
Phillips
A
A
Easterbrook
P
P
Johnson
M
M
Porter
K
K
Schwenk
A
A
Hill
T
T
Leen
C
C
Anderson
J
J
Fisher
M
M
Sabin
C
C
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000639:trends; D015331:Cohort Studies; D005260:Female; D006678:HIV / Q000302:isolation & purification*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology; D016174:Hepacivirus / Q000302:isolation & purification*; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology; D006801:Humans; D016015:Logistic Models; D008297:Male; D016016:Proportional Hazards Models; D016036:Seroepidemiologic Studies; D006113:United Kingdom / Q000453:epidemiology
D018937:Hepatitis C Antibodies